Semaglutide Use in Acute Pulmonary Embolism

NCT06118203 · Completed

Last updated 2026-05-28

This clinical trial is testing whether semaglutide, a medication, affects blood vessel health in adults who have recently experienced a pulmonary embolism.

Status Completed The study has finished.

Type Observational

Participants 18 people

Who can join Ages 18–80 · all sexes

Timeline Started 2022-01 · est. completion 2023-03

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT06118203 ↗

Description as written by the study sponsor.

Evaluation of circulating endothelial inflammatory biomarkers in response to GLP-1 agonist Semaglutide in acute pulmonary embolism

Treatments tested

Semaglutide also known as None applicable Drug

Semaglutide in addition to standard of care

Main thing measured	Endothelial biomarker measurement
Sponsor	Imperial College London
Conditions studied	Pulmonary Embolism
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06118203 ↗